Journal Article

An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans

Stefano Bonassi, Ariana Znaor, Marcello Ceppi, Cecilia Lando, Wushou Peter Chang, Nina Holland, Micheline Kirsch-Volders, Errol Zeiger, Sadayuki Ban, Roberto Barale, Maria Paola Bigatti, Claudia Bolognesi, Antonina Cebulska-Wasilewska, Eleonora Fabianova, Alexandra Fucic, Lars Hagmar, Gordana Joksic, Antonietta Martelli, Lucia Migliore, Ekaterina Mirkova, Maria Rosaria Scarfi, Andrea Zijno, Hannu Norppa and Michael Fenech

in Carcinogenesis

Volume 28, issue 3, pages 625-631
Published in print September 2006 | ISSN: 0143-3334
Published online March 2007 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgl177
An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability subjects were classified according to the percentiles of MN distribution within each laboratory as low, medium or high frequency. A significant increase of all cancers incidence was found for subjects in the groups with medium (RR = 1.84; 95% CI: 1.28–2.66) and high MN frequency (RR = 1.53; 1.04–2.25). The same groups also showed a decreased cancer-free survival, i.e. P = 0.001 and P = 0.025, respectively. This association was present in all national cohorts and for all major cancer sites, especially urogenital (RR = 2.80; 1.17–6.73) and gastro-intestinal cancers (RR = 1.74; 1.01–4.71). The results from the present study provide preliminary evidence that MN frequency in PBL is a predictive biomarker of cancer risk within a population of healthy subjects. The current wide-spread use of the MN assay provides a valuable opportunity to apply this assay in the planning and validation of cancer surveillance and prevention programs.

Journal Article.  5548 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.